Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Corcept Therapeutics Incorporated”

120 pharma patents match "Corcept Therapeutics Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 2 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "Corcept Therapeutics Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “Corcept Therapeutics Incorporated” · 30,257 patents in full index Clear search

  1. US 11890289

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  2. US 11793810

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  3. US 11744837

    Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Sep 5, 2023 · Expires Aug 31, 2043

    granted
  4. US 11684612

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  5. US 11660295

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted May 30, 2023 · Expires May 25, 2043

    granted
  6. US 11648245

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted May 16, 2023 · Expires May 11, 2043

    granted
  7. US 11642331

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted May 9, 2023 · Expires May 4, 2043

    granted
  8. US 11610666

    Systems and methods of managing treatment of a chronic condition by symptom tracking

    Corcept Therapeutics Incorporated · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  9. US 11590113

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  10. US 11590135

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  11. US 11576907

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  12. US 11560379

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  13. US 11542238

    Pyrimidine cyclohexenyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  14. US 11524013

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  15. US 11464764

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Corcept Therapeutics Incorporated · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  16. US 11389432

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  17. US 11370789

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  18. US 11327083

    Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted May 10, 2022 · Expires May 5, 2042

    granted
  19. US 11285145

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Corcept Therapeutics Incorporated · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  20. US 11268145

    Methods for treating Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  21. US 11234971

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  22. US 11213526

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  23. US 11202787

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  24. US 11202784

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted